Indegene liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
9.06×———
2.41×2.41×4.48×2.93×
2.41×2.41×4.48×2.93×
1,1611,4001,531985
1,6401,5321,9661,180
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹593.45

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,272 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)———9.06
Current Ratio2.934.482.412.41
Quick Ratio2.934.482.412.41
Cash, Equiv & ST Investments985.11,530.71,400.31,160.5
Working Capital1,179.91,965.51,532.21,639.6
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.